Tag Archives: science

Allosteric Bioscience: Advancing a First-in-Class Approach to Combat Muscle Degeneration 

28 Apr

By Max Braht, VP of Business Development, LSN

Max-Braht-Headshot

As the global population ages, sarcopenia and age-related muscle loss are emerging as major unmet medical challenges, impacting quality of life, independence, and long-term health outcomes for millions worldwide. With approximately 20% of the global population of 8.2 billion people over age 60, demand for therapies that preserve muscle mass and function is expected to rise significantly.

At the same time, the broader anti-aging market is projected to grow from $73 billion in 2024 to $140 billion by 2034, while the anti-obesity therapeutics market is expected to expand from $16 billion in 2024 to $105 billion by 2030, underscoring the growing commercial relevance of solutions targeting muscle preservation.

Allosteric Bioscience is positioning itself at the forefront of this space with a novel therapeutic strategy designed to preserve muscle mass and function.

Originating from groundbreaking research licensed from Johns Hopkins University, Allosteric Bioscience is developing a small molecule inhibitor of glutamate carboxypeptidase II (GCPII), an enzyme increasingly recognized as a key metabolic regulator in muscle degeneration. By targeting GCPII, the company aims to create a disease-modifying therapy capable of addressing sarcopenia at its biological source rather than simply managing symptoms.

Preclinical studies have demonstrated promising results, including preservation of muscle function, inhibition of muscle wasting, and approximately 20% improvement in survival in relevant disease models. These findings suggest potential applications not only for age-related sarcopenia but also for broader muscle-wasting conditions associated with obesity therapies, chronic disease, and other degenerative disorders.

Allosteric Bioscience’s lead candidates are currently progressing toward IND-enabling studies and advancement into first-in-human clinical development. The company’s broader platform also reflects an ambitious strategy focused on optimizing both lifespan and health-span through innovative aging-related therapeutics.

With leadership from Executive Chairman & Co-Founder, Bruce Meyers, and President & Co-Founder, Dr. Arthur Bollon, Allosteric Bioscience represents a compelling opportunity for investors, strategic partners, and stakeholders interested in next-generation therapeutics targeting one of healthcare’s most pressing aging-related challenges.

As longevity science and preventative therapeutics continue to attract growing investor attention, Allosteric Bioscience is working to redefine how the life sciences industry approaches muscle degeneration and healthy aging.

Learn More & Connect

To learn more about Allosteric Bioscience, visit: allostericbioscience.com

To connect directly with Executive Chairman & Co-Founder Bruce Meyers and President & Co-Founder Dr. Arthur Bollon, schedule a meeting here:

Schedule a Meeting with Allosteric Bioscience

Tags: , , , , , , , , , , , , ,

From Progress to Viability: Economic Risk 

28 Apr

By Dennis Ford, Founder & CEO, Life Science Nation (LSN)

DF-News-09142022

As part of Life Science Nation’s series on converting scientific innovation into investable signal, the focus now shifts to economic risk. After market, technical, regulatory, and execution risks are addressed, the next question becomes whether the product creates enough real-world value to support sustainable adoption.

Economic risk is where value must become viability. Even if a product works and can be approved, it must still fit within the financial realities of healthcare systems, payers, providers, and patients.

This article examines how companies define and validate their economic case through value proposition, pricing strategy, reimbursement pathways, health economic impact, and competitive positioning.

From proving clinical benefit to demonstrating sustainable commercial value, this layer of the De-Risk Stack determines whether innovation can succeed not just scientifically—but economically.

Even if a product works and can be approved, it must still make economic sense within the healthcare systems that will use and pay for it.

Economic risk is often treated as secondary to clinical and technical considerations. In practice, it frequently determines whether adoption occurs at scale and whether the business is sustainable.

The core question is whether the product creates value that is recognized, fundable, and durable.

This begins with the value proposition. The product must deliver a meaningful clinical or economic benefit that is understood by payers, providers, and health systems. The value must be evidence-based, not speculative.

Pricing strategy must then align with that value while remaining acceptable within system constraints. A product priced far above perceived value will struggle; a product priced too low to sustain the business simply moves risk downstream.

A viable reimbursement pathway is essential. This means understanding existing codes, coverage policies, and benefit designs, and knowing whether the product fits into current structures or requires new ones to be established.

Health economic impact and budget impact analyses translate the value story into system terms. Products that improve outcomes at acceptable or lower cost are easier to adopt; products that create near-term budget spikes can face resistance even if they are cost-effective in the long run.

Adoption economics define why providers would choose this product. That includes workflow impact, revenue implications, and perceived risk for clinicians and institutions. Competitive economics compare the full economic case—including acquisition cost, utilization, and downstream impact—against available alternatives.

Economic risk is resolved when the product creates clear, measurable, and fundable value within the actual economic and budget constraints of the system.

Core Elements of Economic Risk

  • Value proposition
  • Pricing strategy
  • Reimbursement pathway
  • Health economic impact
  • Budget impact
  • Adoption economics
  • Competitive economics

Next in the series: Financing Risk — From Opportunity to Investable Campaign

Previous Articles：

  1. Technical Risk – From Belief to Evidence
  2. The Problem Is Not the Science: A Seven-Part Series on De-Risking, Signal, and Investability
  3. From Proof to Approval: Regulatory Risk
  4. From Plan to Progress: Execution Risk

Tags: , , , , , , , , , , , , , , , , ,

From Plan to Progress: Execution Risk 

21 Apr

By Dennis Ford, Founder & CEO, Life Science Nation (LSN)

DF-News-09142022

As part of Life Science Nation’s series on converting scientific innovation into investable signal, the focus now moves to execution risk. Once a company has established market needs, demonstrated technical feasibility, and defined a regulatory path, the next question becomes whether the team can actually deliver.

Execution risks are about the company’s ability to move from strategy to progress. It includes leadership, operational discipline, hiring, partnerships, timelines, and the ability to consistently hit milestones. Even strong science and a compelling opportunity can lose credibility if a company cannot execute against its plan.

This article examines how companies build confidence through clear priorities, realistic timelines, strong teams, and the operational structure needed to keep momentum moving forward.

Execution Risk

From Plan to Progress

With market, technical, and regulatory clarity in place, the question shifts from possibility to delivery: can this actually be executed?

Execution risk reflects whether the company can translate its strategy into measurable progress. Strong science and a well-articulated plan are not enough. Investors are funding the ability to execute under real constraints.

Many companies struggle here not because they lack vision, but because they lack operational discipline. Plans remain high-level, milestones are vague, and capital is deployed without direct linkage to risk reduction.

Execution begins with the team. You need the right mix of scientific, clinical, regulatory, and operational experience for the stage you are in, and leadership that can make decisions under uncertainty. Capability matters, but so does judgment.

Milestone discipline provides structure. Progress must be broken into clear, achievable steps, where each milestone reduces a specific element of risk and moves the company toward a defined value inflection point. A 12-, 24-, and 36-month roadmap ties these milestones together and forces trade-offs.

Operational planning, resource management, and partner oversight determine whether those milestones can be met. Most life science companies depend heavily on CROs, CMOs, and other external partners; selecting and managing them is a central part of execution, not a peripheral task.

Speed and adaptability maintain momentum. Development rarely proceeds linearly. Data will force changes. The ability to adjust direction without losing focus or burning through capital is a defining feature of strong execution.

Governance and structure close the loop. Board composition, information flow, and accountability mechanisms determine how quickly issues are surfaced and addressed. Without this, even high-quality teams drift.

Execution risk is resolved when plans reliably convert into measurable progress and capital consistently turns into risk reduction rather than motion.

Core Elements of Execution Risk

  • Team capability
  • Leadership and decision making
  • Milestone discipline
  • Milestone roadmap
  • Operational plan
  • Resource management
  • External partner management
  • Speed and adaptability
  • Governance and structure

Next in the series: Economic Risk — Defining the Value Creation Opportunity

Previous Articles：

  1. Technical Risk – From Belief to Evidence
  2. The Problem Is Not the Science: A Seven-Part Series on De-Risking, Signal, and Investability
  3. From Proof to Approval: Regulatory Risk

Tags: , , , , , , , , , , , , , , , ,

BioMetas and ZSHK Laboratories Announce Strategic Integration to Build a Full Preclinical CRO Platform

14 Apr

Life Science Nation (LSN) is pleased to highlight an important development from one of our long term partners. BioMetas, Title Sponsor of the RESI conferences in 2026, has announced a strategic integration with ZSHK Laboratories to build a comprehensive preclinical drug discovery and development CRO platform.

This move reflects a continued push toward greater integration across the early stages of drug development, an area where fragmentation has historically slowed progress for emerging companies.

On April 13, 2026, BioMetas Group and ZSHK Laboratories formally completed a strategic integration at BioMetas’ Shanghai headquarters. The signing ceremony included leadership from both organizations as well as representatives from key shareholders, including CFS Capital, Huagai Capital, Qiming Venture Partners, ACM Capital, and the AstraZeneca CICC Fund.

BioMetas has grown rapidly over the past four years as a globally oriented preclinical CRO, with approximately 85 percent of its revenue generated from international clients. The company has developed core capabilities across early research, including protein science, in vitro and in vivo efficacy evaluation, and DMPK, with particular strength in oncology and autoimmune disease programs.

ZSHK Laboratories brings a complementary set of capabilities centered on GLP toxicology services. The company operates internationally certified GLP facilities in Suzhou and Shenzhen and maintains dedicated animal research infrastructure, including non human primate and canine models. Its services span pharmacokinetics, toxicology, and safety evaluation, with a client base primarily concentrated in the domestic Chinese market.

Following the integration, the combined platform is designed to provide a continuous, end to end preclinical development pathway. The service model spans early research, including target validation, molecular screening, and efficacy studies; translational work, including DMPK and dose exploration; and regulatory support, including GLP safety evaluation, toxicology, and safety pharmacology. By consolidating these capabilities within a single platform, the integrated organization aims to reduce handoff between service providers, improve data consistency, and accelerate timelines toward IND.

The integration also strengthens access to experimental animal resources and expands model coverage across multiple species and disease areas, supporting more complex mechanism studies and advanced preclinical programs.

From a strategic standpoint, the companies have indicated a focus on building a broader service plus capital ecosystem, combining scientific capability, operational scale, and capital market alignment to enhance global competitiveness. The transaction reflects a broader trend within the CRO industry toward platform integration, moving beyond cost driven specialization toward more comprehensive, value oriented service models.

For early stage drug development companies, the implication is clear: an integrated preclinical pathway reduces friction, accelerates timelines, and creates a more coherent progression from discovery through IND enabling studies. With this integration, BioMetas strengthens its ability to deliver fast, cost-efficient, high-quality services within a comprehensive platform, positioning itself as a valuable partner for both domestic Chinese innovation and global programs. This combination of speed, efficiency, and execution quality highlights the growing role of leading platforms like BioMetas in moving China further into the forefront of the global early stage drug development landscape.

Tags: , , , , , , , , , , , , , , ,

From Proof to Approval: Regulatory Risk 

14 Apr

By Dennis Ford, Founder & CEO, Life Science Nation (LSN)

DF-News-09142022

As part of Life Science Nation’s series on converting scientific innovation into investable signal, the focus now moves to the next layer of the De-Risk Stack. In the previous article, technical risk addressed whether a product works and can be trusted. The next question is whether it can realistically be approved.

This article examines regulatory risk, where feasibility must become predictability. It outlines how companies define a clear path to approval—covering regulatory pathways, precedent, endpoint selection, trial design, and engagement with regulators.

From aligning with evidence requirements to understanding timelines and cost, this piece breaks down what it takes to move from promising data to an executable plan that investors can underwrite.

Regulatory Risk 

From Feasibility to Predictability

Once the product works, the next question is whether it can be approved.

Regulatory risk is often underestimated because it is treated as an after-the-fact compliance requirement instead of a primary design constraint. In reality, it defines timelines, capital requirements, and feasibility. Without a credible path, investment becomes difficult regardless of how strong the data may be.

The core issue is predictability. Investors need to understand not just that approval is possible, but how it will be achieved, how long it will take, and what it will cost.

This begins with pathway clarity. The regulatory route must be defined early—whether the asset is headed toward an IND and NDA/BLA, a 510(k), a PMA, or another pathway. Precedent provides context by showing how similar products, mechanisms, or indications have been evaluated. Without precedent, uncertainty and perceived risk rise sharply.

Endpoints and trial design then determine whether the plan is executable. Success must be measurable in a way regulators accept, and the required studies must be feasible in terms of recruitment, duration, complexity, and cost. A theoretically elegant trial that cannot be run in the real world is equivalent to having no trial plan at all.

Regulatory interaction further refines the path. Pre-IND or pre-submission meetings align expectations, clarify requirements, and reduce unnecessary iteration. Proceeding without this engagement increases risk and can lead to expensive rework.

Safety requirements, timeline expectations, and the cost of approval define the remaining boundaries. Each indication and modality carries a different tolerance for risk and a different evidence bar, and each pathway implies a specific capital profile.

Regulatory risk is resolved when the path to approval is defined, evidence requirements are understood, and the plan is both credible and executable within known time and capital constraints.

Core Elements of Regulatory Risk 

  • Pathway clarity
  • Precedent
  • Endpoint definition
  • Trial design feasibility
  • Regulatory interaction
  • Safety requirements
  • Timeline predictability
  • Cost of approval

Next in the series: Execution Risk — Turning Plan into Progress 

Previous Articles：

Technical Risk – From Belief to Evidence

The Problem Is Not the Science: A Seven-Part Series on De-Risking, Signal, and Investability

Tags: , , , , , , , , , , , , , , ,

Innovator’s Pitch Challenge Winner Spotlight: Bram De Moor of You2Yourself 

14 Apr

Following its recognition as a winner of the Innovator’s Pitch Challenge at RESI Europe, You2Yourself is advancing a new approach to early disease detection through longitudinal biomarker monitoring. In this interview, Bram De Moor discusses the science behind URIMON, the company’s commercialization strategy, and how RESI has supported its investor engagement. 

Bram De Moor
Founder & General Manager, You2Yourself
 CaitiCaitlin Dolegowski
Program Director, LSN

Caitlin Dolegowski (CD): For those new to You2Yourself, how would you describe URIMON and the value of longitudinal biomarker monitoring in a way that resonates with investors?

Bram De Moor (BD): URIMON is a personalized, non-invasive, urine-based liquid biopsy platform that uses urinary miRNA profiling to detect multiple serious diseases — including prostate cancer, lung cancer, and cardiovascular disease — before symptoms appear. One urine sample generates simultaneous risk scores across multiple conditions.

The longitudinal dimension is key: repeated monitoring detects biological drift months to years before clinical symptoms — the difference between catching cancer at stage I versus stage III. With no needles, no clinic visit, and at-home collection with mail-in capability, URIMON is designed for scalable, population-level adoption.

CD: What makes your approach to early disease detection fundamentally different from traditional diagnostic models?

BD: Traditional diagnostics are reactive and often focus on a single biomarker. URIMON differs in three key ways:

  • Multi-disease detection from a single sample, analyzing hundreds of miRNA species simultaneously
  • Focus on molecular signals rather than anatomical changes, enabling earlier detection
  • Use of urine as a scalable, patient-friendly biofluid that captures signals from across the body

This approach provides a unified molecular health view, reducing fragmentation across specialties.

CD: You have built a unique biobank of longitudinal samples — how does this dataset strengthen your technology and create a competitive advantage?

BD: The URIMON Biobank, developed since 2019 with over 6,500 participants under IRB-approved and GDPR-compliant protocols, is a significant strategic moat.

It enables algorithm training on longitudinal patient data, including individuals who later develop disease, supporting prospective validation. It also ensures robustness across cohorts, allowing classifiers to generalize beyond a single institution.

Replicating this dataset would require years and substantial capital, making it a durable barrier to entry.

CD: How do you think about commercialization, particularly your subscription-based model and the path toward broader reimbursement and population-level adoption?

BD: Our strategy is staged to de-risk scaling. We are entering the market under the EU IVDR Article 5(5) in-house LDT framework to accelerate time to revenue.

Our subscription model (€299–499/year) targets individuals, employer groups, and occupational health programs, aligning recurring revenue with longitudinal monitoring.

Reimbursement will follow through HTA submissions in Europe, with FDA De Novo clearance as a parallel pathway in the U.S.

CD: What key milestones or inflection points should investors be watching as you move toward your planned 2027 market entry?

BD: Key milestones include:

  • Clinical validation and publication of performance data
  • Regulatory progress under IVDR and FDA pathways
  • Launch of commercial infrastructure and first paying customers
  • Strategic partnerships and completion of financing rounds
  • These milestones will demonstrate both technical validation and commercial traction.

CD: How did participating in RESI Europe and the Innovator’s Pitch Challenge impact your investor visibility and strategic conversations?

BD: RESI provided direct access to European and transatlantic investors actively seeking early-stage diagnostic companies — a highly targeted audience that is difficult to reach through traditional outreach.

The Innovator’s Pitch Challenge offered structured validation in a competitive setting, signaling credibility to institutional investors. It also led to new investor conversations and follow-up meetings now underway.

CD: Following your recognition at RESI Europe, what are the next key priorities for You2Yourself as you move into your next phase of growth?

BD: Our focus over the next 12–18 months includes:

  • Expanding clinical evidence through continued biobank growth and prospective studies
  • Securing financing through grants and a seed-to-Series A bridge round
  • Scaling team and infrastructure across lab, regulatory, and business development functions

With favorable market conditions — including advances in NGS, growing demand for preventive health, and regulatory clarity — You2Yourself is well positioned to lead in this space.

Applications are now open for upcoming Innovator’s Pitch Challenges. Companies can apply to pitch at RESI San Diego 2026 and take the stage in front of a global network of investors and partners.

Apply to Pitch at RESI San Diego

Tags: , , , , , , , , , , , , , , , , , , , , , , , , , , , ,

The Needle Issue #25

14 Apr
Juan-Carlos-Lopez
Juan Carlos Lopez		 Andy-Marshall
Andy Marshall

The approval of multiple anti-amyloid monoclonal antibodies (mAbs) — aducanumab (Aduhelm; now withdrawn), lecanemab (Leqembi) and donanemab (Kisunla) — over the past five years has opened the era of disease-modifying Alzheimer’s drugs, albeit with only modest benefits in addressing cognitive decline (30% slowing) and associated serious safety risks, such as CNS inflammation and cerebral hemorrhages, which has limited clinical uptake. While many drug development programs target biological processes other than amyloid formation (e.g., tau and tangles, neurotransmitter receptors, neuroinflammation, autophagy, and mitochondrial or metabolic dysfunction), companies continue to optimize anti-amyloid monoclonals, but also look for alternative ways to therapeutically target Aβ.

One alternative therapeutic modality to antibodies is chimeric antigen receptor (CAR) immune cell therapy. In recent weeks, we have been thinking a lot about in vivo chimeric antigen receptor (CAR)-T therapies, which were one of the dealmaking trends in 2025, and we recommend readers check out an excellent summary of trends in the area from the consultancy firm Scitaris (you don’t even have to give them your details to download the report).

CAR-T treatments have established their clinical niche as last-ditch treatments for B-cell malignancies, with some remarkable outcomes for late-stage patients. In some cases, they have been shown to be at least twice as effective as T-cell engager bispecific antibodies in clinical studies. But they remain rather blunt instruments.

Despite advances in the clinical management of cytokine-release syndrome and immune effector cell neurotoxicity syndrome (ICANS), CAR-T treatments continue to be associated with serious risks. And while there have been advances in managing these adverse events, atypical non-ICANS neurotoxicities (NINTs) can also create serious clinical management issues, with risk factors predisposing patients to development still only poorly understood.

That said, over the past year, we have seen an increasing trend for the use of CAR-T treatments outside oncology. They have started to be applied with promising efficacy in various areas of autoimmunity (systemic lupus erythrematosus, lupus nephritis, systemic sclerosis, Sjögren’s syndrome, antisynthetase syndrome, myasthenia gravis and idiopathic inflammatory myopathies) and neuroinflammatory conditions (multiple sclerosis). In this respect, a recent paper in Science caught our attention. In it, Marco Colonna and his colleagues at Washington University in St. Louis harness astrocytes to clear amyloid plaques by promoting their ability to phagocytize Aβ.

To that end, they used in vivo gene therapy to generate astrocytes carrying chimeric antigen receptors (“CAR-As”), a strategy not unlike the one used in cancer immunotherapy. Although both macrophages (CAR-Ms) and conventional CAR-Ts have been tested in preclinical models of Alzheimer’s disease with limited success, this study reports the first attempt to directly engineer astrocytes in the body to generate CAR-As.

In broad terms, the construct used to generate CAR-As consisted of an Aβ-binding domain and the phagocytic signaling protein MEGF10 (multiple epidermal growth factor-like domains protein 10). The team examined a variety of constructs and chose two for in vivo testing. One of them combined a fragment from the Aβ-binding antibody crenezumab and MEGF10, which is primarily expressed in astrocytes. The second construct combined a fragment of aducanumab with the phagocytosis receptor Dectin-1, which is primarily expressed in microglia.

The authors packaged the constructs in an adeno-associated viral (AAV) vector under the control of an astrocyte-specific promoter and injected them intravenously into 5xFAD mice (which carry five familial Alzheimer’s disease (FAD) mutations, driving rapid Aβ plaque formation, synaptic loss, and cognitive decline starting around 2–4 months). Both CAR-As reduced amyloid burden and neuritic dystrophy, and the treatment worked both in the prophylactic and therapeutic settings.

Single-nucleus RNA sequencing and immunostaining showed that the CAR-As adopted the transcriptomic profile of activated astrocytes and readily clustered around amyloid plaques. Microglial cells, in turn, also responded to the treatment by showing a reduction of the disease-associated transcriptomic profile that is often seen after administration of monoclonal anti-Aβ antibodies. This is of interest because this disease profile of microglial cells has been suggested to contribute to the inflammatory reaction sometimes seen after Alzheimer’s immunotherapy.

A caveat of the study is that the authos saw no improvements in cognition following therapy, albeit behavioral results in mouse models have been notoriously poor at predicting outcomes in humans. However, the translational questions don’t stop there.

If in clinical practice the CAR-A approach would require an AAV vector, then immunogenicity of the treatment is going to be an issue. Pre-exposure to AAV is often a problem for gene-therapy programs, where patients are much younger. Given that Alzheimer’s is a disease associated with an elderly population, immunogenicity is likely to be exacerbated. Similarly, the delivery of 1013–1014 viral genomes to elderly patients living with Alzheimer’s—many of whom will already have a brain prone to neuroinflammation—makes the specter of unwanted side effects a major concern. In this respect, finding Alzheimer’s patients whose disease stage and age would be appropriate for a therapy with potentially highly toxic consequences for fragile recipients is also difficult to gauge.

That is not to say that CAR-immune cell therapy may not have a place in CNS disease. It just seems like neurological conditions, such as multiple sclerosis where patients are younger and potentially less fragile, are the place where much of the translational groundwork and clinical management for CAR-A or CAR-T therapies must be worked out before moving into neurodegenerative disease for elderly and cognitively compromised patients.

Tags: , , , , , , , , , , , , , , , , , , , , , , , , , , , , ,

← Older Entries
Newer Entries →